Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation
- Resource Type
- Abstract
- Source
- In
The Breast October 2018 41 Supplement 1:S27-S28 - Subject
- Language
- ISSN
- 0960-9776